Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
ARQT Stock Chart & Stats
$28.97
-$0.25(-1.59%)
At close: 4:00 PM EST
$28.97
-$0.25(-1.59%)
Day’s Range― - ―
52-Week Range$11.13 - $31.77
Previous CloseN/A
Volume446.87K
Average Volume (3M)2.27M
Market Cap
$3.55B
Enterprise Value$2.43B
Total Cash (Recent Filing)$191.07M
Total Debt (Recent Filing)$6.28M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Mar 03, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding122,492,195
10 Day Avg. Volume2,151,998
30 Day Avg. Volume2,266,800
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)10.70
Price to Sales (P/S)8.57
P/FCF Ratio-15.00
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue7.63
Enterprise Value/Gross Profit8.49
Enterprise Value/Ebitda-101.34
Forecast
1Y Price Target
$30.25Price Target Upside4.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market Leadership And PotentialZoryve is currently the leader in the branded anti-inflammatory topical class and has the potential to treat approximately 17 million patients across multiple indications.
Product Sales And GrowthTotal product sales beat consensus handily by approximately 14%, driven by demand growth and improvement in GTN.
Regulatory Success And Market ExpansionThe FDA approval of a new Zoryve cream formulation for pediatric atopic dermatitis is a significant milestone for Arcutis Biotherapeutics.
Bears Say
Market CompetitionCommercial success is not assured since dermatology remains a highly competitive segment of the market.
Medicare Reimbursement ChallengesManagement noted that Medicare reimbursement has stalled due to IRA-related changes, impacting less than 25% of the company’s target market.
Product Concentration RiskProduct concentration risk exists since Zoryve is the company's only commercial asset and its pipeline assets are in early-stage development.
Arcutis Biotherapeutics News
ARQT FAQ
What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $11.13 and its highest was $31.77 in the past 12 months.
What is Arcutis Biotherapeutics’s market cap?
Arcutis Biotherapeutics’s market cap is $3.55B.
When is Arcutis Biotherapeutics’s upcoming earnings report date?
Arcutis Biotherapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 64 days.
How were Arcutis Biotherapeutics’s earnings last quarter?
Arcutis Biotherapeutics released its earnings results on Oct 01, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.094 by $0.154.
Is Arcutis Biotherapeutics overvalued?
According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
Does Arcutis Biotherapeutics pay dividends?
Arcutis Biotherapeutics does not currently pay dividends.
What is Arcutis Biotherapeutics’s EPS estimate?
Arcutis Biotherapeutics’s EPS estimate is 0.07.
How many shares outstanding does Arcutis Biotherapeutics have?
Arcutis Biotherapeutics has 122,492,195 shares outstanding.
What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
Arcutis Biotherapeutics reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.094. Following the earnings report the stock price went up 4.828%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
Currently, no hedge funds are holding shares in ARQT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcutis Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.25 (4.42% Upside)
$30.25 (4.42% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 90%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 25.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.03%
12-Months-Change
Fundamentals
Return on Equity
-28.17%
Trailing 12-Months
Asset Growth
-15.18%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
ARQT Company Deck
ARQT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Arcutis Biotherapeutics highlighted strong revenue and prescription growth driven by the ZORYVE franchise and recent FDA approval. Despite seasonal factors expected to moderate growth and challenges in Medicare Part D coverage, the positive cash flow and strategic plans suggest a promising outlook.View all ARQT earnings summariesARQT Stock 12 Month Forecast
Average Price Target
$30.25
▲(4.42% Upside)
Technical Analysis
Travere Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
9.47% Insiders
16.24% Mutual Funds
56.20% Other Institutional Investors
5.12% Public Companies and Individual Investors